Lantheus (NASDAQ:LNTH) Releases FY 2026 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.000-5.250 for the period, compared to the consensus earnings per share estimate of 5.160. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday. Truist Financial boosted their target price on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Citizens Jmp increased their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Finally, Mizuho upped their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $78.83.

Lantheus Price Performance

NASDAQ:LNTH opened at $75.72 on Thursday. The firm’s fifty day moving average is $67.76 and its two-hundred day moving average is $59.90. The firm has a market cap of $5.02 billion, a price-to-earnings ratio of 31.82 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus has a one year low of $47.25 and a one year high of $111.29.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts expect that Lantheus will post 6.01 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LNTH. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after buying an additional 1,950,252 shares during the period. Dimensional Fund Advisors LP raised its stake in Lantheus by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock valued at $94,202,000 after acquiring an additional 44,374 shares during the last quarter. Carmignac Gestion lifted its position in Lantheus by 39.0% during the 4th quarter. Carmignac Gestion now owns 1,122,000 shares of the medical equipment provider’s stock worth $74,669,000 after acquiring an additional 314,591 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Lantheus by 0.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 817,247 shares of the medical equipment provider’s stock valued at $54,388,000 after purchasing an additional 5,337 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Lantheus by 31.1% in the fourth quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock valued at $44,082,000 after purchasing an additional 156,081 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.